AF
NAMS icon

Avanza Fonder’s NewAmsterdam Pharma NAMS Stock Holding History

Avanza Fonder’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,566
Closed -$230K – 502
2025
Q4 		$230K Sell
6,566
-939
-13% -$34.2K 0.01% 418
2025
Q3 		$213K Hold
7,505
– – 0.01% 385
2025
Q2 		$136K Buy
7,505
+1,300
+21% +$23.7K ﹤0.01% 401
2025
Q1 		$113K Buy
+6,205
New +$138K ﹤0.01% 431

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Avanza Fonder's NAMS Position: Q1 2026 in Review

Avanza Fonder sold out of NewAmsterdam Pharma (NAMS) in Q1 2026, closing a stake of 6,566 shares — an estimated $230K sold.

Avanza Fonder first reported a position in NAMS in Q1 2025 and held it in 4 quarters. The position peaked at $230K in Q4 2025. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Avanza Fonder reported no remaining NewAmsterdam Pharma position as of Q1 2026 after selling out during the quarter.
  • Avanza Fonder sold 6,566 NewAmsterdam Pharma shares in Q1 2026, an estimated $230K.
  • Avanza Fonder first reported a position in NewAmsterdam Pharma in Q1 2025 and held it in 4 quarters.
  • Avanza Fonder's NewAmsterdam Pharma position peaked at $230K in Q4 2025.
  • 170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Avanza Fonder's 13F filing for Q1 2026, filed 15 Apr 2026.